Leadership - InSphero

Leadership

InSphero’s leadership team combines rich scientific and commercial expertise in 3D microtissue engineering, cell-based assays, laboratory automation, and industry-scale production and quality assurance. The strategic management expertise of our Board of Directors and Strategic Advisory Board members complements our leadership scheme.

Management Team

Jan Lichtenberg, PhD
Jan Lichtenberg, PhD
Chief Executive Officer, Co-Founder
 
Prof. Armin Wolf, PhD
Prof. Armin Wolf, PhD
Chief Scientific Officer
 
Filip Henzler
Filip Henzler
Chief Financial Officer
 
Paul Edgard Clémençon, MBA
Paul Edgard Clémençon, MBA
Head of Business Development
 
Wolfgang Moritz, PhD
Wolfgang Moritz, PhD
Head of External Collaborations & IP
 
Marion Bavand, PhD, MBA
Marion Bavand, PhD, MBA
Head of Quality Assurance 
 
Stina Näslund, MSc
Stina Näslund, MSc
Head of Human Resources
 
David Fluri, PhD
David Fluri, PhD
Head of Operations
 
Olivier Frey, PhD
Olivier Frey, PhD
Vice President, Technology and Platforms
 
Burcak Yesildag, PhD
Burcak Yesildag, PhD
Vice President, Diabetes Research
 
Bruno Filippi, PhD
Bruno Filippi, PhD
Vice President, Liver Safety
 
Francisco Verdeguer, PhD
Francisco Verdeguer, PhD
Vice President, Liver Discovery
 

Dr. Jürg Gysi, President of the Board, Switzerland

Former CEO, Promega AG Switzerland. Molecular Biologist with more than 30 years of experience in sales, marketing and management in the biotech industry in Switzerland, Germany and the US.

Dr. Jan Lichtenberg, Chief Executive Officer InSphero AG, Member of the InSphero Management Team

Co-founder of InSphero, former Head of R&D and Product Management in medical-device company Hocoma AG and Uwatec AG. Entrepreneur of the Year Switzerland in 2013 and ETH Zurich, University of Neuchâtel, EPF Lausanne and University of Bremen alumni. Founder and former CEO of Advanced Micromachining Tools GmbH.

Thomas Pfisterer, Wild Group Management AG

Heads the Direct Investments activities of the WILD Family Office since beginning of 2015. He joined the Family Office following the sale of WILD Flavors GmbH, one of the world’s leading suppliers of natural ingredients to the food and beverage industry, which he served as Head of Strategic Development directing the company’s global M&A activities since October 2011. Previously, Mr. Pfisterer worked in the investment banking division of Morgan Stanley Bank AG in Frankfurt focusing on M&A and capital market transactions for German healthcare clients. Mr. Pfisterer holds a Master in Finance (MPhil) from Cambridge University, as well as a Bachelor in Economics (B.A. HSG) and a Bachelor in Business Administration (B.A. HSG) both from University of St. Gallen.

Beat Schillig, Founder and President IFJ Institute for Young Entrepreneurs

Serial Entrepreneur and Business Angel.

Daniel Kallay, Global Head of New Business Development, Red Bull GmbH

Served as managing director for Red Bull France, Southern Europe and Switzerland previously and is board member on a number of Swiss technology companies. He holds a Master of Economics degree from the University of St. Gallen (HSG) and an advanced leadership degree from Cambridge University.

Prof. Nikolai Naoumov, MD, PhD

Prof. Naoumov is a is distinguished physician-scientist, with a professional career spanning academia, clinical care, and drug development. He is a Fellow of both the Royal College of Physicians (London) and the Royal College of Pathologists (UK). His research has integrated immunology, molecular biology, and translational medicine in elucidating virus-host interactions and mechanisms of liver injury.

Prof. Thomas Hartung, MD, PhD

Prof. Hartung is a Professor of Evidence-based Toxicology and Director of the Center for Alternatives to Animal Testing at Johns Hopkins University Bloomberg School of Public Health, and Professor of Pharmacology and Toxicology at the University of Konstanz. He is a passionate advocate for replacing animal testing with more ethical and predictive in vitro models and is investigating new applications for big data and artificial intelligence in toxicity testing.

Prof. Matthias von Herrath, MD

Prof. von Herrath holds a dual appointment as Vice President and Senior Medical Officer at Novo Nordisk and Professor at the La Jolla Institute for Immunology Center for Autoimmunity and Inflammation. One of the world’s leading type 1 diabetes researchers, he is committed to clinical translation of immune-based interventions in autoimmune and metabolic diseases.

Prof. Gerd Kullak-Ublick, MD

Prof. Kullak-Ublick is a Full Professor and Director of the Department of Clinical Pharmacology and Toxicology at the University Hospital Zurich. His primary research interests include function and regulation of drug transporters, new biomarkers of drug safety, and drug-induced liver and kidney injury. Prof. Kullak-Ublick’s contributions in the fields of pharmacology, toxicology, gastroenterology, and hepatology have received critical acclaim and recognition from honorable subject experts around the world.